July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Retrospective analysis of intravitreal incections for age related macular degeneration (ARMD) from 2012 to 2016
Author Affiliations & Notes
  • Gerhard Kieselbach
    ophthalmology, Medical University, Innsbruck, Austria
  • Claus Zehetner
    ophthalmology, Medical University, Innsbruck, Austria
  • martina kralinger
    ophthalmology, Medical University, Innsbruck, Austria
  • inga waltl
    ophthalmology, Medical University, Innsbruck, Austria
  • anna vavrovsky
    MH, Vienna, Austria
  • Footnotes
    Commercial Relationships   Gerhard Kieselbach, None; Claus Zehetner, None; martina kralinger, None; inga waltl, None; anna vavrovsky, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2395. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gerhard Kieselbach, Claus Zehetner, martina kralinger, inga waltl, anna vavrovsky; Retrospective analysis of intravitreal incections for age related macular degeneration (ARMD) from 2012 to 2016. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2395.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (ARMD) in the real-life setting and to compare number of injections per year with visual acuity at baseline and four years after injections administered by physicians.

Methods : Retrospective, single-centre study. Medical records of patients receiving anti-VEGF treatment for ARMD between 2012 and 2016 were evaluated. Outcome measures were baseline visual acuity (VA), change in VA and number of intravitreal injections per eye.

Results : For this study 1876 patients receiving intravitreal injections between 2012 and 2016 were identified. The records of 1156 patients were evaluated for this study. 1156 patients received a total of 13 127 intravitreal anti-VEGF injections over four years. 28 % of patients received treatment for both eyes. VA was obtained in 654 eyes, which were treated for four years. The mean baseline VA was 0.32. The mean change of VA from baseline was -2 letters and the mean numbers of injections were 4.7 and 4.1 at years 1 and year 2, respectively. There was a positive correlation between change of VA and number of injections per eye. However, more than 40% had VA of 0.32 or better.

Conclusions : Real life data show not more than 15% of patients with ARMD receiving 6 ore more injections per year. Mean injections per year and eye were 4.4 for right eyes and 3.2 for left eyes. Patients receiving injections for both eyes had higher numbers of injections than patients treated for one eye. VA could be maintained in one third of all patients.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×